These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 23165803)
1. Endocytic regulation of voltage-dependent potassium channels in the heart. Ishii K; Norota I; Obara Y J Pharmacol Sci; 2012; 120(4):264-9. PubMed ID: 23165803 [TBL] [Abstract][Full Text] [Related]
2. Expression of voltage-gated K+ channels in human atrium. Bertaso F; Sharpe CC; Hendry BM; James AF Basic Res Cardiol; 2002 Nov; 97(6):424-33. PubMed ID: 12395204 [TBL] [Abstract][Full Text] [Related]
3. Accessory Kvbeta1 subunits differentially modulate the functional expression of voltage-gated K+ channels in mouse ventricular myocytes. Aimond F; Kwak SP; Rhodes KJ; Nerbonne JM Circ Res; 2005 Mar; 96(4):451-8. PubMed ID: 15662035 [TBL] [Abstract][Full Text] [Related]
4. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels. Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690 [TBL] [Abstract][Full Text] [Related]
5. Short-term effects of rapid pacing on mRNA level of voltage-dependent K(+) channels in rat atrium: electrical remodeling in paroxysmal atrial tachycardia. Yamashita T; Murakawa Y; Hayami N; Fukui Ei; Kasaoka Y; Inoue M; Omata M Circulation; 2000 Apr; 101(16):2007-14. PubMed ID: 10779469 [TBL] [Abstract][Full Text] [Related]
6. Modulation of HERG potassium channels by extracellular magnesium and quinidine. Po SS; Wang DW; Yang IC; Johnson JP; Nie L; Bennett PB J Cardiovasc Pharmacol; 1999 Feb; 33(2):181-5. PubMed ID: 10028924 [TBL] [Abstract][Full Text] [Related]
7. On the mechanism by which 4-Aminopyridine occludes quinidine block of the cardiac K+ channel, hKv1.5. Chen FS; Fedida D J Gen Physiol; 1998 Apr; 111(4):539-54. PubMed ID: 9524137 [TBL] [Abstract][Full Text] [Related]
8. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Brendel J; Peukert S Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):273-87. PubMed ID: 15326917 [TBL] [Abstract][Full Text] [Related]
9. Theoretical possibilities for the development of novel antiarrhythmic drugs. Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Zitron E; Kiesecker C; Scholz E; Lück S; Bloehs R; Kathöfer S; Thomas D; Kiehn J; Kreye VA; Katus HA; Schoels W; Karle CA Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):146-56. PubMed ID: 15322737 [TBL] [Abstract][Full Text] [Related]
15. The impact of ancillary subunits on small-molecule interactions with voltage-gated potassium channels. Panaghie G; Abbott GW Curr Pharm Des; 2006; 12(18):2285-302. PubMed ID: 16787255 [TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of the maximum conductance of Kv1.5 channels by extracellular K+ reduction and acidification. Fedida D; Zhang S; Kwan DC; Eduljee C; Kehl SJ Cell Biochem Biophys; 2005; 43(2):231-42. PubMed ID: 16049348 [TBL] [Abstract][Full Text] [Related]
17. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Spector PS; Curran ME; Keating MT; Sanguinetti MC Circ Res; 1996 Mar; 78(3):499-503. PubMed ID: 8593709 [TBL] [Abstract][Full Text] [Related]
18. The 1997 Stevenson Award Lecture. Cardiac K+ channel gating: cloned delayed rectifier mechanisms and drug modulation. Fedida D; Chen FS; Zhang X Can J Physiol Pharmacol; 1998 Feb; 76(2):77-89. PubMed ID: 9635145 [TBL] [Abstract][Full Text] [Related]
19. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. Rampe D; Roy ML; Dennis A; Brown AM FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]